Global Oral Antidiabetic Drugs Market, By Drug Class (Biguanides, Thiazolidinediones, Dipeptidyl Peptidase IV Inhibitors, α-Glucosidase Inhibitors, Insulin Secretagogues, Amylin Analog, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2027
Market Analysis and Insights: Global Oral Antidiabetic Drugs Market
Oral antidiabetic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Rising prevalence of diabetes worldwide and emerging markets are the factors responsible for the growth of this market.
Growing cases of type 2 diabetes drives the oral antidiabetic drugs market. Due to the adaptation of unhealthy lifestyle, environment pollution and family history with diabetes disease also boost up the oral antidiabetic drugs market growth. However, rapidly changing lifestyle and expanding number of diabetic patients globally will boost up the global oral antidiabetic drugs market. But, accessibility of alternative treatment and discrepancy in reimbursement may hamper the global oral antidiabetic drugs market.
Diabetes is a disease with high glucose level in the blood resulting deficiency of insulin in the body. Drugs which are used for the treatment of diabetes called as antidiabetic drugs. These agents help in reducing blood glucose level by activation of glycogen phosphorylase, and gluconeogenic enzymes, revealed decreased rates of glycogenolysis and gluconeogenesis. Increased activities of glucose-6-phosphate dehydrogenase and glycolytic enzymes.
Oral antidiabetic drugs market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Oral Antidiabetic Drugs Market Scope and Market Size
The oral antidiabetic drugs market is segmented on the basis of drug class, end-users and distribution channel.
- On the basis of drugs class, the oral antidiabetic drugs market is segmented into biguanides, thiazolidinediones, dipeptidyl peptidase IV inhibitors, α-glucosidase inhibitors, insulin secretagogues, amylin analog, sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonist and others. Insulin secretagogues further segmented into sulfonylureas & meglitinides.
- On the basis of end-users, the oral antidiabetic drugs market is segmented into hospitals, specialty clinics and others
- On the basis of distribution channel, oral antidiabetic drugs market has also been segmented into hospital pharmacy, retail pharmacy others
Oral Antidiabetic Drugs Market Country Level Analysis
Oral antidiabetic drugs are analysed and market size information is provided by country, drug class, end-users and distribution channel as referenced above.
The countries covered in the oral antidiabetic drugs market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, in the Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
North America holds the largest market share due to rapidly increasing smoking & obesity population and presence of key manufacture of the product. Europe is considered second largest market for oral antidiabetic drugs due to high research and development and healthcare expenditure and skilled professionals. Asia-Pacific is expected to account for the highest market share over coming years for the oral antidiabetic drugs market due to enhanced prevalence of diabetes and related disorders and number of generic drugs.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Global oral antidiabetic drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Oral Antidiabetic Drugs Market Share Analysis
Global oral antidiabetic drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to oral antidiabetic drugs market.
The major players covered in the oral antidiabetic drugs market are Novartis AG, Eli Lilly and Company, Merck & Co., Inc, Novo Nordisk A/S, Johnson & Johnson Services, Inc., Teva Pharmaceuticals Pvt Ltd., F. Hoffmann-La Roche Ltd., Sanofi, and among others.
Customization Available: Global Oral Antidiabetic Drugs Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.